Invectys administers $17m series A

Invectys, a France-based biopharmaceutical spinout of Institut Pasteur, raised €15m ($17m) in series A funding on Monday led by an unnamed family office.
The round also featured unnamed, existing shareholders and assorted private investors.
Founded in 2010, Invectys is working on immuno-oncology treatments for patients suffering from haematological and solid tumours. Its lead candidate, Invac-1, is a DNA vaccine aimed at chronic lymphocytic leukaemia.
The funding will go towards a phase 2 clinical trial of Invac-1 conducted at MD Anderson Cancer Center.
Invectys previously secured a total of $26m, including $4.9m in July 2017 from unnamed, existing backers. The July 2017 figure included more than $1.1m in public funding secured by the company up until that point from state-owned investment bank Bpifrance.
The company had previously disclosed a $7.6m funding round in 2016 and a $1.8m funding round in 2015, with backers each time including unnamed, existing shareholders made up of family offices and private investors.
Pierre Langlade-Demoyen, co-founder and CEO of Invectys, said: “It is really exciting to move into a phase 2 clinical trial, especially at the MD Anderson Cancer Center, the world’s foremost hospital for cancer therapy.
“We are very pleased to have on board new investors from the Houston area as well as our historic investors. Products like Invac-1 are poised to emerge as mainstream components to combination immune-oncology regimens.”